Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review

References

• Riggs BL, Melton LJ 3rd, Robb RA, et al. Population based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004;19(12):1945–1954.
   PubMed Web of Science ®Google Scholar
• Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys. 2010;503(1):118–128.
   PubMed Web of Science ®Google Scholar
• Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015;37(8):1837–1850.
   PubMed Web of Science ®Google Scholar
• Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11–15.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Gaughran F, Mitchell AJ, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126–133.
   PubMed Web of Science ®Google Scholar
• Nazrun AS, Tzar MN, Mokhtar SA, et al. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag. 2014;10:937–948.
   PubMed Web of Science ®Google Scholar
• Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136.
   PubMed Web of Science ®Google Scholar
• Stubbs B, De Hert M, Sepehry AA, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130:470–86.
   PubMed Web of Science ®Google Scholar
• Tsai K-Y, Lee C-C, Chou Y-M, et al. The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study. Schizophr Res. 2014;159:322–328.
   PubMed Web of Science ®Google Scholar
• Wu H, Deng L, Zhao L, et al. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol. 2013;2013:167138.
   PubMedGoogle Scholar
• Kishimoto T, De Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25:415–429.
   PubMed Web of Science ®Google Scholar
• Abel KM, Heatlie HF, Howard LM, et al. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. J Clin Psychiatry. 2008;69:1398–1403.
   PubMed Web of Science ®Google Scholar
• Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641–657.
   PubMed Web of Science ®Google Scholar
• Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65:1607–1618.
   PubMed Web of Science ®Google Scholar
• Okita K, Kanahara N, Nishimura M, et al. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014;157:137–141.
   PubMed Web of Science ®Google Scholar
• Partti K, Heliövaara M, Impivaara O, et al. Skeletal status in psychotic disorders: a population-based study. Psychosom Med. 2010;72:933–940.
   PubMed Web of Science ®Google Scholar
• Jung D-U, Kelly DL, Oh M-K, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406–410.
   PubMed Web of Science ®Google Scholar
• Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol. 2008;22:38–45.
   PubMedGoogle Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291–2314.
   PubMed Web of Science ®Google Scholar
• Lean M, De Smedt G. Schizophrenia and osteoporosis. Int Clin Psychopharmacol. 2004;19:31–35.
   PubMed Web of Science ®Google Scholar
• Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 2003;28(Suppl 2):97–108.
   PubMed Web of Science ®Google Scholar
• Crews MPK, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27:15–23.
   PubMed Web of Science ®Google Scholar
• Graham SM, Howgate D, Anderson W, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10:575–602.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385–391.
   PubMed Web of Science ®Google Scholar
• Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull. 1996;22:447–454.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.
   PubMed Web of Science ®Google Scholar
• Tseng P-T, Chen Y-W, Yeh P-Y, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore) 2015;94(47):e1967.
   Google Scholar
• Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133–135.
   PubMed Web of Science ®Google Scholar
• Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychoticinduced hyperprolactinemia. J Clin Psychiatry. 2010;71(9):1131–1137.
   PubMed Web of Science ®Google Scholar
• Bishop JR, Rubin LH, Reilly JL, et al. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther Adv Psychopharmacol. 2012;2(3):95–102.
   PubMedGoogle Scholar
• Meaney AM, O’Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93(1–3):136–143.
   PubMed Web of Science ®Google Scholar
• Lodhi RJ, Masand S, Malik A, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophr Res. 2016;170(2–3):245–251.
   PubMed Web of Science ®Google Scholar
• Lupsa BC, Insogna K. bone health and osteoporosis. Endocrinol Metab Clin North Am. 2015;44(3):517–530.
   PubMed Web of Science ®Google Scholar
• Emkey GR, Epstein S. Secondary osteoporosis: pathophysiology & diagnosis. Best Pract Res Clin Endocrinol Metab. 2014;28(6):911–935.
   PubMed Web of Science ®Google Scholar
• Bernabei R, Martone AM, Ortolani E, et al. Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab. 2014;11(3):201–207.
   PubMedGoogle Scholar
• World Health Organization (WHO). Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1–164.
   Google Scholar
• World Health Organization (WHO) (2007). WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report, 2004 May 5–7. Brussels (Belgium): WHO.
   Google Scholar
• International Osteoporosis Foundation. [cited 12 Oct 2015] Available from: http://www.iofbonehealth.org.
   Google Scholar
• O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70–75.
   PubMedGoogle Scholar
• Gong B, Mandair GS, Wehrli FW, et al. Novel assessment tools for osteoporosis diagnosis and treatment. Curr Osteoporos Rep. 2014;12(3):357–365.
   PubMed Web of Science ®Google Scholar
• O’Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26–31.
   PubMed Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503–508.
   PubMed Web of Science ®Google Scholar
• Leslie WD. Clinical review: Ethnic differences in bone mass–clinical implications. J Clin Endocrinol Metab. 2012;97(12):4329–4340.
   PubMed Web of Science ®Google Scholar
• Watts NB, Leslie WD, Foldes AJ, et al. 2013 International Society for Clinical Densitometry Position Development Conference: task force on normative databases. J Clin Densitom. 2013;16(4):472–481.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Mundt C, et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(8):1195–1201.
   PubMed Web of Science ®Google Scholar
• Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162(1):162–167.
   PubMed Web of Science ®Google Scholar
• Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int. 2012;23(8):2081–2092.
   PubMed Web of Science ®Google Scholar
• Calarge CA, Ivins SD, Motyl KJ, et al. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Ther Adv Psychopharmacol. 2013;3(5):278–293.
   PubMedGoogle Scholar
• Vasikaran S, Eastell R, Bruyère O, et al. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?. Ann Clin Biochem. 2010;47(Pt 4):292–300.
   PubMed Web of Science ®Google Scholar
• van der Leeuw C, Peeters S, Domen P, et al. bone mineral density as a marker of cumulative estrogen exposure in psychotic disorder: a 3 year follow-up study. PLoS One. 2015;10(8):e0136320.
   Google Scholar
• Kinon BJ, Liu-Seifert H, Stauffer VL, et al. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin Schizophr Relat Psychoses. 2013;7(3):115–123.
   PubMedGoogle Scholar
• Byerly M, Suppes T, Tran Q-V, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639–661.
   PubMed Web of Science ®Google Scholar
• Bataille-Simoneau N, Gerland K, Chappard D, et al. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun. 1996;229(1):323–328.
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Krishnamra N, Van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem. 2009;107(4):677–685.
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Thongchote K, Charoenphandhu N, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 2008;42(3):535–546.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Assessment of fracture risk. Eur J Radiol. 2009;71(3):392–397.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009;5(8):425–431.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589.
   PubMed Web of Science ®Google Scholar
• Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(Suppl):SS75–S86.
   PubMed Web of Science ®Google Scholar
• Wyszogrodzka-Kucharska A, Rabe-Jablonska J. Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics. Eur Neuropsychopharmacol. 2006;16(Suppl. 4):S373–4.
   Google Scholar
• Stubbs B, Gardner-Sood P, Smith S, et al. Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. Schizophr Res. 2015;168(1–2):461–464.
   PubMed Web of Science ®Google Scholar
• Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2007;42:268–276.
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res. 2006;82:225–231.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Physical activity guidelines for Americans. Washington: US Dept of Health and Human Services; 2016. Available from: http://health.gov/paguidelines/pdf/paguide.pdf [cited 2016 Jan 13].
   Google Scholar
• De Hert M, Vancampfort D, Detraux J. Somatic problems and dual disorder patients. In: Dom G, Moggi F, editors. Co-occurring addictive and psychiatric disorders: a practice-based handbook from a European perspective. Berlin: Springer; 2015. p. 349–362.
   Google Scholar
• De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–157.
   PubMed Web of Science ®Google Scholar
• Fini M, Salamanna F, Veronesi F, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686–2706.
   PubMedGoogle Scholar
• Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155–162.
   PubMed Web of Science ®Google Scholar
• Ko CH, Chan RLY, Siu WS, et al. Deteriorating effect on bone metabolism and microstructure by passive cigarette smoking through dual actions on osteoblast and osteoclast. Calcif Tissue Int. 2015;96(5):389–400.
   PubMed Web of Science ®Google Scholar
• Marinucci L, Bodo M, Balloni S, et al. Sub-toxic nicotine concentrations affect extracellular matrix and growth factor signaling gene expressions in human osteoblasts. J Cell Physiol. 2014;229(12):2038–2048.
   PubMed Web of Science ®Google Scholar
• Abate M, Vanni D, Pantalone A, et al. Cigarette smoking and musculoskeletal disorders. Muscles Ligaments Tendons J. 2013;3(2):63–69.
   PubMedGoogle Scholar
• Li J, Zhang F-Q, Du Z-N, et al. Protective effect of HO-1 transfection against ethanol-induced osteoblast damage. J Huazhong Univ Sci Technolog Med Sci. 2015;35(3):374–377.
   PubMed Web of Science ®Google Scholar
• Guañabens N, Parés A. Management of osteoporosis in liver disease. Clin Res Hepatol Gastroenterol. 2011;35(6–7):438–445.
   PubMed Web of Science ®Google Scholar
• Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008;121(5):406–418.
   PubMed Web of Science ®Google Scholar
• Chen L-C, Bai Y-M, Chang M-H. Polydipsia, hyponatremia and rhabdomyolysis in schizophrenia: a case report. World J Psychiatry. 2014;4(4):150–152.
   PubMedGoogle Scholar
• Hawken ER, Crookall JM, Reddick D, et al. Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: a retrospective study. Schizophr Res. 2009;107(2–3):128–133.
   PubMed Web of Science ®Google Scholar
• Delva NJ, Crammer JL, Jarzylo SV, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry. 1989;26(8):781–793.
   PubMed Web of Science ®Google Scholar
• Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. 2013;5(1):51–108.
   PubMedGoogle Scholar
• Belvederi Murri M, Respino M, Masotti M, et al. Vitamin D and psychosis: mini meta-analysis. Schizophr Res. 2013;150(1):235–239.
   PubMed Web of Science ®Google Scholar
• Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–254.
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, Vancampfort D, et al. Severe mental illness and diabetes mellitus type 2. Die Psychiatrie. 2012;9(3):159–164.
   Google Scholar
• Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132(2):144–157.
   PubMed Web of Science ®Google Scholar
• Shanbhogue VV, Mitchell DM, Rosen CJ, et al. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4(2):159–173.
   PubMed Web of Science ®Google Scholar
• Booth AK, Gutierrez-Hartmann A. Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol. 2015;846:37–59.
   PubMed Web of Science ®Google Scholar
• Dandinoğlu T, Akarsu S, Tekin L, et al. A 22-year-old man with severe osteoporosis due to prolactinoma. J Clin Rheumatol. 2013;19(6):341–343.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gan X, Luo P, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945–948.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Mormando M, et al. Vertebral fractures in males with prolactinoma. Endocrine. 2011;39(3):288–293.
   PubMed Web of Science ®Google Scholar
• Naliato EC, Farias ML, Braucks GR, et al. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(1):12–17.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf). 2000;52(3):319–327.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Lin C-Y, Huang T-L, et al. Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(2):96–102.
   PubMed Web of Science ®Google Scholar
• Wang M, Hou R, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183–189.
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Kinon BJ, Ahl J, et al. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci. 2004;1032:297–298.
   PubMed Web of Science ®Google Scholar
• Abraham G, Halbreich U, Friedman RH, et al. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res. 2003;59(1):17–18.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Uchida H, John M, et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2–3):383–386.
   PubMed Web of Science ®Google Scholar
• Lin C-H, Huang K-H, Chang Y-C, et al. Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol. 2012;15(7):897–906.
   PubMed Web of Science ®Google Scholar
• Keely E, Reiss JP, Drinkwater DT, et al. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract. 1997;3(4):209–213.
   PubMedGoogle Scholar
• Rey-Sánchez P, Lavado-García JM, Canal-Macías ML, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24(1):49–54.
   PubMed Web of Science ®Google Scholar
• van der Leeuw C, Habets P, Domen P, et al. for G.R.O.U.P. Bone mineral density as a marker of cumulative endogenous estrogen exposure: relationship to background genetic risk of psychotic disorder. Schizophr Res. 2013;143(1):25–31.
   PubMed Web of Science ®Google Scholar
• Sugawara N, Yasui-Furukori N, Fujii A, et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol. 2011;26(8):596–601.
   PubMed Web of Science ®Google Scholar
• Lee T-Y, Chung M-Y, Chung H-K, et al. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig. 2010;7(4):278–284.
   PubMed Web of Science ®Google Scholar
• Renn JH, Yang NP, Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord. 2010;11:35.
   PubMed Web of Science ®Google Scholar
• Jung DU, Conley RR, Kelly DL, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391–1396.
   PubMed Web of Science ®Google Scholar
• Howes OD, Wheeler MJ, Meaney A-M, et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol. 2005;25(3):259–261.
   PubMed Web of Science ®Google Scholar
• Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64(7):761–766.
   PubMed Web of Science ®Google Scholar
• Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry. 2003;160(9):1618–1620.
   PubMed Web of Science ®Google Scholar
• Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. [Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics]. Psychiatr Pol. 2005;39(6):1173–1184.
   PubMedGoogle Scholar
• Tests and Procedures. Bone density test. [cited 2016 Jan 11]. Available from: http://www.mayoclinic.org/tests-procedures/bone-density-test/basics/results/prc-20020254.
   Google Scholar
• Crabtree NJ, Arabi A, Bachrach LK, et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17(2):225–242.
   PubMed Web of Science ®Google Scholar
• Demirdas S, Coakley KE, Bisschop PH, et al. Bone health in phenylketonuria: a systematic review and meta-analysis. Orphanet J Rare Dis. 2015 Feb;15(10):17.
   Web of Science ®Google Scholar
• Wade SW, Strader C, Fitzpatrick LA, et al. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014;9:182.
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57(5):485–491.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Laughlin GA, Li H, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2012;27(11):2306–2313.
   PubMed Web of Science ®Google Scholar
• Wu C-S, Chang C-M, Tsai Y-T, et al. Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case-control study. J Clin Psychiatry. 2015;76(9):1216–1223.
   PubMed Web of Science ®Google Scholar
• Järvinen TL, Michaëlsson K, Aspenberg P, et al. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277(6):662–673.
   PubMed Web of Science ®Google Scholar
• Sørensen HJ, Jensen SOW, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872–878.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Vancampfort D, Bobes J, et al. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand. 2015;132(2):122–130.
   PubMed Web of Science ®Google Scholar
• Morgan JLL, Skulan JL, Gordon GW, et al. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci U S A. 2012;109(25):9989–9994.
   PubMed Web of Science ®Google Scholar
• Komori T. Animal models for osteoporosis. Eur J Pharmacol. 2015;759:287–294.
   PubMed Web of Science ®Google Scholar
• Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.
   PubMedGoogle Scholar
• Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010;123(10):877–884.
   PubMed Web of Science ®Google Scholar
• Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014.
   PubMed Web of Science ®Google Scholar
• Frenkel B, White W, Tuckermann J. Glucocorticoid-induced osteoporosis. Adv Exp Med Biol. 2015;872:179–215.
   PubMed Web of Science ®Google Scholar
• INVEGA® (paliperidone). Highlights of prescribing information. April 2014. [cited 30 Oct 2015]. Available from: http://www.invega.com/prescribing-information.
   Google Scholar
• RISPERDAL® (risperidone). Highlights of prescribing information. April 2014. [cited 2015 Oct 30] Available from: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/risperdal.pdf.
   Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807–816.
   PubMed Web of Science ®Google Scholar